Abstract
Hematopietic Progenitor Cells (HPC-C) from cord blood (CB) are used in the treatment of hematopoetic malignancies, marrow failure syndromes (MFS), hereditary immune and erythropoetic disorders. The directed banking model for CB preserves units for use in a sibling with a diagnosis that is currently treatable with stem cell transplantation. The resulting outcomes of 106 related allogeneic cord blood transplants are herein reported.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
